Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07718243 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

Study acronym: BLAZE
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Aug 2026 to Aug 28, 2026
    • Site details revised at 1 of 2 sites
    v4
  2. Site contacts updated at 1 of 2 sitesv3
  3. Recruitment opened
    • Start date: Jul 2026 to Aug 2026
    • Site details revised at 2 of 2 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma. Early research suggests bexmarilimab may change some immune cells inside the tumour so they create a stronger "attack" signal, which could help other immune cells recognise and kill cancer cells more effectively. This may make it easier for PD-1 immunotherapy drugs to work again by helping the immune system stay active against the tumour. This is a Phase I/II clinical trial. In Phase I, researchers will give increasing doses of bexmarilimab together with a standard (fixed) dose of nivolumab to patients with solid tumours, to find the safest and most suitable dose to use going forward (the recommended Phase 2 dose). In Phase II, the study will treat two groups of patients-one with non-small cell lung cancer and one with melanoma-using that selected dose.
Trial Details
NCT Number NCT07718243
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Faron Pharmaceuticals Ltd, The Christie NHS Foundation Trust, Royal Marsden NHS Foundation Trust
Conditions
(from sponsor)		 Melanoma (Skin Cancer), Non Small Cell Lung Cancer, Solid Tumor in Advanced Stage
Related terms Carcinoma, Non-Small-Cell Lung, Melanoma
Enrollment 62 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov